The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
Launched by ENES FARUK ALTUNKILIÇ · Jun 19, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a common medication called methylphenidate, used to treat children with Attention Deficit Hyperactivity Disorder (ADHD), affects certain markers in the blood that are related to brain inflammation. The researchers want to see if starting this treatment changes levels of specific substances linked to inflammation in the brain over a period of three months. Understanding this could help explain how the medication works beyond just improving attention and behavior.
Children between the ages of 6 and 11 who have been diagnosed with ADHD and are about to begin or have just started methylphenidate treatment may be eligible to join. To participate, children should not have other psychiatric conditions, ongoing infections, or chronic illnesses, and they should not have used psychiatric medications before. If eligible, participants will have blood samples taken before starting the medication and again three months later to measure the inflammation markers. This study is not yet recruiting, but it aims to provide new insights into how ADHD treatment affects brain health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. According to DSM-5 TR, the participant must have a diagnosis of "Attention Deficit Hyperactivity Disorder" and have started/be planning to start routine methylphenidate treatment.
- • 2. The participant must be between 6 and 11 years of age.
- • 3. The participant must agree to participate in the study after being informed about it.
- Exclusion Criteria:
- • 1. The presence of a psychiatric disorder diagnosis other than Attention Deficit Hyperactivity Disorder
- • 2. Having a diagnosis of Attention Deficit Hyperactivity Disorder but not planning to start methylphenidate
- • 3. Being under 6 years of age or over 11 years of age
- • 4. Having organic brain damage, mental retardation, autism spectrum disorder, neurological disease, or a physical illness that affects neurocognitive functions
- • 5. History of alcohol and/or psychoactive substance use
- • 6. Presence of ongoing active infection, allergic disease, and chronic illness
- • 7. Previous use of psychiatric medication.
- • 8. Presence of chronic illness
- • 9. Regular use of medication
About Enes Faruk Altunkiliç
Enes Faruk Altunkiliç is a clinical trial sponsor dedicated to advancing medical research through the design and oversight of high-quality clinical studies. With a focus on ensuring scientific rigor and patient safety, Altunkiliç contributes to the development of innovative therapeutic solutions aimed at improving health outcomes. His involvement encompasses the coordination of multidisciplinary teams and adherence to regulatory standards, reflecting a commitment to ethical and impactful clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported